Aim: To compare the efficacy of thioridazine and tiapride in treatment of hyperkinetic behavioral disorders (HBD) in children.
Material And Methods: The study included 60 children, детей, 42 boys and 18 girls, mean age 8.0±2.0 years. Patients were divided into two equal groups. The duration of the study was 30 days. The Achenbach System of Empirically Based Assessment (ASEBA) was used. Safety was assessed by sedation scores and serum prolactin levels.
Results And Conclusion: A positive effect of both drugs was shown. The levels of aggression and delinquency decreased significantly, while a decrease in attention levels was less pronounced. Both drugs were similar by efficacy, but tiapride had better safety profile.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17116/jnevro20181182131-34 | DOI Listing |
Tremor Other Hyperkinet Mov (N Y)
January 2025
Department of Neurology, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, US.
Background: Myoclonus is a hyperkinetic movement with various attributable etiologies, semiologies, and treatment outcomes. To our knowledge, few studies investigated adult-onset myoclonus in an inpatient setting.
Methods: We retrospectively reviewed charts of adult inpatients with myoclonus at New York Presbyterian Brooklyn Methodist Hospital between 2011 and 2021.
Am J Hum Genet
January 2025
Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Institute of Human Genetics, University of Regensburg, 93053 Regensburg, Germany; Institute of Clinical Human Genetics, University Hospital Regensburg, 93053 Regensburg, Germany. Electronic address:
BCL11B is a Cys2-His2 zinc-finger (C2H2-ZnF) domain-containing, DNA-binding, transcription factor with established roles in the development of various organs and tissues, primarily the immune and nervous systems. BCL11B germline variants have been associated with a variety of developmental syndromes. However, genotype-phenotype correlations along with pathophysiologic mechanisms of selected variants mostly remain elusive.
View Article and Find Full Text PDFPharmaceuticals (Basel)
December 2024
División de Neurociencias Básicas, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, SSa, Calzada México-Xochimilco 289, Arenal de Guadalupe, Ciudad de México 14389, Mexico.
Parkinson's disease is associated with the loss of more than 40% of dopaminergic neurons in the substantia nigra pars compacta. One of the therapeutic options for restoring striatal dopamine levels is the administration of L-3,4-dihydroxyphenylalanine (L-Dopa). However, Parkinson's disease patients on long-term L-Dopa therapy often experience motor complications, such as dyskinesias.
View Article and Find Full Text PDFPsychopharmacol Bull
January 2025
Alamiri, MD, ABPN, ScD, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait.
Herein, authors report on an ASD child with comorbid ADHD, ID, metabolic syndrome and nocturnal enuresis that failed multiple trials of psychotropic agents for behavioural dyscontrol. Viloxazine adjuventia brought about remarkable improvement spanning different domains. Purported pharmacodynamic mechanisms are briefly discussed.
View Article and Find Full Text PDFJ Vet Intern Med
December 2024
Small Animal Hospital, School of Veterinary Medicine, University of Glasgow, Glasgow, United Kingdom.
Background: Episodic ataxias (EAs) are a rare group of paroxysmal movement disorders (PMD) described in human medicine with only one suspected case described in veterinary literature.
Hypothesis/objectives: This study aimed to provide clinical description of a suspected primary EA in working Cocker Spaniel (WCS) dogs.
Animals: Seven WCS dogs with suspected primary EA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!